Provenge Approval Would Include Surveillance For Cerebrovascular Events
Executive Summary
A pharmacovigilence study involving roughly 3,000 patients would be conducted by Dendreon to monitor safety events associated with Provenge, if FDA approves the therapeutic cancer vaccine
You may also be interested in...
Provenge Survival Data Plagued by Small Study Size, Post hoc Analysis
The Cellular, Tissue and Gene Therapies Advisory Committee's favorable recommendation on the efficacy of Dendreon's Provenge could give FDA greater confidence in accepting the post hoc survival analysis and approving the cancer vaccine
Sanofi Looks To Enter Cancer Vaccine Field With TroVax Acquisition
A collaboration between Sanofi-Aventis and Oxford BioMedica in the area of therapeutic cancer vaccines could extend beyond the development of TroVax to second-generation therapeutic vaccines combining technology from both companies, Sanofi Senior VP-Head of Oncology Allain Herrera said
Sanofi Looks To Enter Cancer Vaccine Field With TroVax Acquisition
A collaboration between Sanofi-Aventis and Oxford BioMedica in the area of therapeutic cancer vaccines could extend beyond the development of TroVax to second-generation therapeutic vaccines combining technology from both companies, Sanofi Senior VP-Head of Oncology Allain Herrera said